Basis of narrow-spectrum activity of fidaxomicin on gut pathogen Clostridioides difficile
Cao, X.; Boyaci, H.; Chen, J.; Bao, Y.; Landick, R.; Campbell, E. A.
Show abstract
Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections (CDIs), but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains enigmatic. CDIs are a leading cause of nosocomial deaths. Fdx, which inhibits RNA polymerase (RNAP), targets Cdiff with minimal effects on gut commensals, reducing CDI recurrence. Here, we present the cryo-electron microscopy structure of Cdiff RNAP in complex with Fdx, allowing us to identify a crucial Fdx-binding determinant of Cdiff RNAP that is absent in most gut microbiota like Proteobacteria and Bacteroidetes. By combining structural, biochemical, and bioinformatic analyses, we establish that a single RNAP residue is a sensitizing element for Fdx narrow-spectrum activity. Our results provide a blueprint for targeted drug design against an important human pathogen.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Ornithine capture by a translating ribosome controls bacterial polyamine synthesis 99%
- Structures of the stator complex that drives rotation of the bacterial flagellum 98%
- The cut site specificity of the influenza A virus endoribonuclease PA-X allows it to discriminate between host and viral mRNAs 98%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.